Conducted in a Research or GCP environment, these assays are part of IMMUNOGRAM*, a multi-parameter approach that offers a personalized and dynamic “fingerprint” of tumor-immune system interaction.
By combining IMMUNOSCORE® expertise with advanced technologies, HalioDx delivers high-added value data and analysis to understand tumor immune contexture, identify patients more likely to respond to therapy, characterize biomarkers of treatment response or resistance, foster the development of robust assays (CTAs, CDx).
IMMUNOGRAM can be customized and used either in prospective and retrospective settings or in translational research studies.
* Adapted from Blank CU. et al., Science (2016)